Welcome to our dedicated page for AlloVir news (Ticker: ALVR), a resource for investors and traders seeking the latest updates and insights on AlloVir stock.
AlloVir, Inc. (NASDAQ: ALVR) is a leading entity in the clinical-stage biotech sector, focusing on allogeneic T cell immunotherapy for viral diseases affecting immunocompromised patients. The company is dedicated to the research, development, and commercialization of innovative T-cell therapies designed to restore natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems.
AlloVir is known for its proprietary technology platforms that produce off-the-shelf, multi-virus-specific T cells. These cells are used to address the urgent medical needs of patients suffering from viral-associated diseases. The company’s lead product candidate, posoleucel, has been in clinical trials for the prevention and treatment of infections caused by six common and devastating viruses, including adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus-6 (HHV-6), and JC virus (JCV).
Despite the promise of posoleucel, AlloVir recently announced the discontinuation of its three global Phase 3 studies due to futility analyses that showed the studies were unlikely to meet their primary endpoints. However, the studies did not identify any safety concerns, maintaining the potential for further exploration of posoleucel in other contexts.
AlloVir’s pipeline also includes ALVR106, targeted at respiratory infections like respiratory syncytial virus (RSV), human metapneumovirus (hMPV), influenza, and parainfluenza virus (PIV), now completing Phase 1b/2a clinical trials. Additionally, ALVR107 aims to address chronic hepatitis B with preclinical studies supporting its potential efficacy.
Founded in 2013 and based in Waltham, Massachusetts, AlloVir continues to evaluate strategic options for its future, including mergers, sales, divestitures, or licensing opportunities. With substantial capital in reserves, AlloVir is positioned to explore and advance its mission to treat and prevent viral diseases.
For more detailed information, visit AlloVir's website or follow the company on LinkedIn and Twitter.
AlloVir has announced a merger with Kalaris Therapeutics in an all-stock transaction. The combined company will focus on developing TH103, a novel anti-VEGF therapy for retinal diseases, invented by Dr. Napoleone Ferrara. After the merger, pre-Merger AlloVir stockholders will own 25.05% and Kalaris stockholders 74.95% of the combined company. The merged entity will have approximately $100 million in cash, providing runway into Q4 2026, and will trade as Kalaris Therapeutics (KLRS) on Nasdaq. TH103 is currently in Phase 1 trials for neovascular age-related macular degeneration, with initial data expected in Q3 2025. The therapy targets the $14 billion global branded anti-VEGF retinal market.
FAQ
What is the current stock price of AlloVir (ALVR)?
What is the market cap of AlloVir (ALVR)?
What is AlloVir, Inc.?
What does AlloVir's lead product candidate, posoleucel, target?
Why were the Phase 3 trials for posoleucel discontinued?
What other products are in AlloVir’s pipeline?
What are AlloVir's future plans?
Where is AlloVir based?
How can I follow AlloVir’s updates?
Who is the CEO of AlloVir, Inc.?
When was AlloVir founded?
What was the financial status of AlloVir as of September 2023?
